MindMaze Therapeutics Home Rehab Program Triples Training Dose
MindMaze Therapeutics' home-based rehabilitation program showed a threefold increase in training dose and significant improvements in patient functional measures.
GENEVA, SWITZERLAND – MindMaze Therapeutics has reported new real-world evidence from its home-based rehabilitation program. A multi-site initiative demonstrated that home rehabilitation using the MindMotion system increased the motor training dose threefold compared to standard outpatient therapy.
The program found that 84% of the active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility, and cognition, alongside high patient satisfaction.
These findings support MindMaze Therapeutics' strategy to extend high-dose, high-intensity neurorehabilitation into patients' homes. This is particularly relevant ahead of the company's upcoming launch of MindMotion Lite, expected by year-end 2026.
MindMotion Lite is a tablet-based solution designed to deliver MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, aiming to simplify home deployment and support broader adoption by healthcare providers.